Zurex Pharma Inc., a Baird Capital Portfolio company, has raised $9 million ahead of its pending New Drug Application submission and review by the U.S. Food and Drug Administration for its first product, ZurexPrep. The capital will also support development activities.

The medical technology company’s shareholders led its equity financing with the aid of a debt financing from Square 1 Bank.

“Our team is grateful for our strong and supportive investor base and glad to have Square 1 on board as our financial services partner,” Zurex President and CEO Carmine Durham said.

ZurexPrep is designed for presurgical skin preparation to prevent surgical site infections (SSIs). SSIs are the most expensive health facility-acquired infection, which can cost from $3.5 billion to $10 billion each year.

“Successful clinical development and regulatory approval of the ZurexPrep product line further validates our antimicrobial platform and opens up numerous opportunities for a portfolio of new infection prevention and wound care products,” Durham said.